Bristol-Myers doubles down on PsiOxus in $936M-plus “armed” oncolytic virus deal
Bristol-Myers Squibb $BMY is taking its relationship with PsiOxus to the proverbial next level. The big biotech is grabbing rights to the Oxford-based company’s next-gen oncolytic virus therapy, which employs a trio of tumor cell-killing approaches to rein in cancer.
Already allied on a combination of Opdivo with PsiOxus’ leading oncolytic virus, enadenotucirev, Bristol-Myers has come back for NG-348, an “armed” oncolytic virus that adds immuno-therapeutic transgenes to the cancer cell destroying mix. Bristol-Myers is offering $50 million upfront, along with new research support and up to $886 million in milestones if all the cards turn in its favor.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters